Government-Owned Inventions; Availability for Licensing, 11845 [2024-03121]

Download as PDF Federal Register / Vol. 89, No. 32 / Thursday, February 15, 2024 / Notices as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Rockville, MD 20852 by contacting Dawn Taylor-Mulneix at 301–451–8021 or dawn.taylor-mulneix@nih.gov. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished information related to the invention. SUPPLEMENTARY INFORMATION: Technology description follows: Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID New Innovators Awards (DP2 Clinical Trial Not Allowed). Date: March 11–13, 2024. Time: 10:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20852 (Video Assisted Meeting). Contact Person: Vanitha Sundaresa Raman, Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, MSC 9834, Rockville, MD 20852, 301–761–7949, vanitha.raman@ nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) Equipping Natural Killer Cells With a CD28H-Containing Chimeric Antigen Receptor To Overcome Inhibition for Cancer Immunotherapy Dated: February 12, 2024. Lauren A. Fleck, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2024–03195 Filed 2–14–24; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: • Method of adoptive cell therapy where CAR–NK cells are the effective cell. National Institutes of Health, Notice. The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained by communicating with the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, khammond on DSKJM1Z7X2PROD with NOTICES SUMMARY: VerDate Sep<11>2014 18:36 Feb 14, 2024 Jkt 262001 Immunotherapy with chimeric antigen receptor (CAR) cytotoxic T cells have been successful in the clinical treatment of hematologic cancers; however adverse side effects such as severe cytokine release syndrome and neurotoxicity are associated with CAR– T cell infusion. CAR natural killer (NK) cells represent a viable alternative with demonstrated advantages over CAR–T cells for the elimination of tumor cells, but NK inhibitory cell receptors need to be reduced or overridden. To overcome this challenge, scientists at NIAID have developed CAR constructs that overcome inhibition of NK cells by receptors for human major histocompatibility complex molecules HLA–E and HLA–C, based on in vitro studies. NK cells that are expressing variants of this invention robustly overcome inhibition imposed by CD19+ HLA–I+ tumor cells and are cytotoxic to them. This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration. Potential Commercial Applications HHS. ACTION: Description of Technology Competitive Advantages 11845 HLA Class I for adoptive transfer of CAR–NK Cells. Front. Immunol. 13:840844. https://www.frontiersin.org/ articles/10.3389/fimmu.2022.840844/ full. May 2, 2022. Zhuang X. and Long E.O., ‘‘CD28 homolog is a strong activator of Natural Killer cells for lysis of B7H7-positive tumor cells.’’ Cancer Immunol. Res. 7(6):939–951. https://cancerimmunol res.aacrjournals.org/content/7/6/ 939.long. April 24, 2019. Zhuang X, Long E.O. ‘‘Inhibitionresistant CARs for NK cell cancer immunotherapy.’’ Trends Immunol. 40(12):1078–1081.https://www.science direct.com/science/article/pii/ S1471490619302133?via%3Dihub. November 12, 2019. Intellectual Property: HHS Reference No. E–097–2020; Patent Application Nos.: PCT Application No. PCT/ US2020/02498, US: 17/914,027, Australia: 2020437669, Brazil: BR112022017512–4, Canada: 3174779, Europe: 20719313.7, India: 2022170585054, Japan: 2022–557764, South Korea: 10–2022–7037236. Licensing Contact: To license this technology, please contact Dawn TaylorMulneix at 301–451–8021 or dawn.taylor-mulneix@nih.gov, and reference E–097–2020. Collaborative Research Opportunity: The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Dawn Taylor-Mulneix at 301– 451–8021 or dawn.taylor-mulneix@ nih.gov. Dated: February 9, 2024. Surekha Vathyam, Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases. [FR Doc. 2024–03121 Filed 2–14–24; 8:45 am] BILLING CODE 4140–01–P • CD28H CAR–NK cells induce a more robust anti-tumor cytotoxic activity compared to third generation CAR–T cells and are more potent in overcoming inhibition. • CAR–NK can be developed without the need of genetic silencing of TCR. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Developmental Stage Office of the Director; Notice of Charter Renewal • Pre-clinical. Inventors: Eric Long, Ph.D. and Xiaoxuan Zhuang, both of NIAID. Publications: Zhuang X., Long E.O., ‘‘NK cells equipped with a chimeric antigen receptor that overcomes inhibition by In accordance with Title 41 of the U.S. Code of Federal Regulations, Section 102–3.65(a), notice is hereby given that the charter for the Cures Acceleration Network Review Board, was renewed for an additional two-year period on February 7, 2024. PO 00000 Frm 00037 Fmt 4703 Sfmt 4703 E:\FR\FM\15FEN1.SGM 15FEN1

Agencies

[Federal Register Volume 89, Number 32 (Thursday, February 15, 2024)]
[Notices]
[Page 11845]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-03121]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained 
by communicating with the Technology Transfer and Intellectual Property 
Office, National Institute of Allergy and Infectious Diseases, 5601 
Fishers Lane, Rockville, MD 20852 by contacting Dawn Taylor-Mulneix at 
301-451-8021 or [email protected]. A signed Confidential 
Disclosure Agreement will be required to receive copies of unpublished 
information related to the invention.

SUPPLEMENTARY INFORMATION: Technology description follows:

Equipping Natural Killer Cells With a CD28H-Containing Chimeric Antigen 
Receptor To Overcome Inhibition for Cancer Immunotherapy

Description of Technology

    Immunotherapy with chimeric antigen receptor (CAR) cytotoxic T 
cells have been successful in the clinical treatment of hematologic 
cancers; however adverse side effects such as severe cytokine release 
syndrome and neurotoxicity are associated with CAR-T cell infusion. CAR 
natural killer (NK) cells represent a viable alternative with 
demonstrated advantages over CAR-T cells for the elimination of tumor 
cells, but NK inhibitory cell receptors need to be reduced or 
overridden. To overcome this challenge, scientists at NIAID have 
developed CAR constructs that overcome inhibition of NK cells by 
receptors for human major histocompatibility complex molecules HLA-E 
and HLA-C, based on in vitro studies. NK cells that are expressing 
variants of this invention robustly overcome inhibition imposed by 
CD19\+\ HLA-I\+\ tumor cells and are cytotoxic to them.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as 
well as for further development and evaluation under a research 
collaboration.

Potential Commercial Applications

     Method of adoptive cell therapy where CAR-NK cells are the 
effective cell.

Competitive Advantages

     CD28H CAR-NK cells induce a more robust anti-tumor 
cytotoxic activity compared to third generation CAR-T cells and are 
more potent in overcoming inhibition.
     CAR-NK can be developed without the need of genetic 
silencing of TCR.

Developmental Stage

     Pre-clinical.
    Inventors: Eric Long, Ph.D. and Xiaoxuan Zhuang, both of NIAID.
    Publications:
    Zhuang X., Long E.O., ``NK cells equipped with a chimeric antigen 
receptor that overcomes inhibition by HLA Class I for adoptive transfer 
of CAR-NK Cells. Front. Immunol. 13:840844. https://www.frontiersin.org/articles/10.3389/fimmu.2022.840844/full. May 2, 
2022.
    Zhuang X. and Long E.O., ``CD28 homolog is a strong activator of 
Natural Killer cells for lysis of B7H7-positive tumor cells.'' Cancer 
Immunol. Res. 7(6):939-951. https://cancerimmunolres.aacrjournals.org/content/7/6/939.long. April 24, 2019.
    Zhuang X, Long E.O. ``Inhibition-resistant CARs for NK cell cancer 
immunotherapy.'' Trends Immunol. 40(12):1078-1081.https://
www.sciencedirect.com/science/article/pii/S1471490619302133?via%3Dihub. 
November 12, 2019.
    Intellectual Property: HHS Reference No. E-097-2020; Patent 
Application Nos.: PCT Application No. PCT/US2020/02498, US: 17/914,027, 
Australia: 2020437669, Brazil: BR112022017512-4, Canada: 3174779, 
Europe: 20719313.7, India: 2022170585054, Japan: 2022-557764, South 
Korea: 10-2022-7037236.
    Licensing Contact: To license this technology, please contact Dawn 
Taylor-Mulneix at 301-451-8021 or [email protected], and 
reference E-097-2020.
    Collaborative Research Opportunity: The National Institute of 
Allergy and Infectious Diseases is seeking statements of capability or 
interest from parties interested in collaborative research to further 
develop, evaluate, or commercialize this technology. For collaboration 
opportunities, please contact Dawn Taylor-Mulneix at 301-451-8021 or 
[email protected].

    Dated: February 9, 2024.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2024-03121 Filed 2-14-24; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.